Lemzoparlimab Biosimilar – Anti-CD47 mAb – Research Grade

Description of Lemzoparlimab Biosimilar - Anti-CD47 mAb - Research Grade

Introduction

Lemzoparlimab Biosimilar, also known as Anti-CD47 mAb, is a promising therapeutic antibody that has gained significant attention in the field of cancer research. This biosimilar is designed to target the CD47 protein, which is known to be overexpressed in various types of cancer cells, making it a potential therapeutic target for cancer treatment. In this article, we will explore the structure, activity, and potential applications of Lemzoparlimab Biosimilar in the field of cancer research.

Structure of Lemzoparlimab Biosimilar

Lemzoparlimab Biosimilar is a monoclonal antibody (mAb) that is designed to mimic the structure of the human immune system’s natural antibodies. It is a fully humanized IgG4 antibody, meaning that it is composed of four subunits, two heavy chains, and two light chains. The heavy chains are responsible for the antibody’s binding activity, while the light chains play a role in regulating the immune response.

The unique structure of Lemzoparlimab Biosimilar allows it to specifically target the CD47 protein, which is overexpressed on the surface of cancer cells. This protein acts as a “don’t eat me” signal, preventing the cancer cells from being recognized and destroyed by the body’s immune system. By binding to CD47, Lemzoparlimab Biosimilar blocks this signal, allowing the immune system to recognize and eliminate cancer cells.

Activity of Lemzoparlimab Biosimilar

Lemzoparlimab Biosimilar has shown promising activity in preclinical studies, demonstrating its ability to specifically bind to CD47 and block its function. This results in the activation of phagocytosis, a process in which immune cells engulf and destroy cancer cells. By enhancing this natural immune response, Lemzoparlimab Biosimilar has the potential to effectively eliminate cancer cells.

Additionally, Lemzoparlimab Biosimilar has also been shown to have an immunomodulatory effect, meaning it can regulate the immune response in the tumor microenvironment. This can lead to a reduction in tumor growth and metastasis, making it a potential therapeutic option for various types of cancer.

Applications of Lemzoparlimab Biosimilar

Lemzoparlimab Biosimilar has shown promising results in preclinical studies for the treatment of various types of cancer, including acute myeloid leukemia, non-Hodgkin’s lymphoma, and solid tumors such as breast and ovarian cancer. It has also been shown to enhance the efficacy of other cancer therapies, such as chemotherapy and radiation therapy.

In addition to its potential as a therapeutic option, Lemzoparlimab Biosimilar is also being studied for its diagnostic and prognostic capabilities. As CD47 is overexpressed in many types of cancer, measuring its levels in the blood or tissue samples may serve as a biomarker for cancer detection and monitoring of treatment response.

Conclusion

Lemzoparlimab Biosimilar, also known as Anti-CD47 mAb, is a promising therapeutic antibody with a unique structure and activity. By specifically targeting the CD47 protein, it has the potential to activate the body’s immune response against cancer cells. This biosimilar has shown promising results in preclinical studies and has the potential to be a valuable treatment option for various types of cancer. Further research and clinical trials are needed to fully understand the potential of Lemzoparlimab Biosimilar in the field of cancer research.

Lemzoparlimab Biosimilar - Anti-CD47 mAb binds to CD47 Recombinant Protein (Human) in indirect ELISA Assay

Immobilized CD47 Recombinant Protein (Human) (cat. No.PX-P4083) at 0.5µg/mL (100µL/well) can bind to Lemzoparlimab Biosimilar - Anti-CD47 mAb (cat. No.PX-TA1677) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450